Drug Profile
HS 1421
Alternative Names: HS1421Latest Information Update: 26 Sep 2006
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Class Heart failure therapies
- Mechanism of Action Atrial peptide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic nephropathies; Heart failure